

# ACURIAN CASE STUDY:

Predictable, reliable, and  
measurable results

## Acurian Helped to Put a Sponsor at the Forefront of a Chronic Disease Market


This sponsor was in a crucial race in the diabetes space as it began phase III clinical trials for a new class of drug for type 2 diabetes.

**They were also rolling into a crowded field of companies developing competitive compounds.**


The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to \$50 billion by 2022.

**Acurian played a key role in winning the race to market.** Knowing that a compound that gets to market first generally maintains the lead throughout the product's lifecycle, the clinical trial team hired Acurian to provide enrollment support for eight protocols.

- Across all protocols supported, we increased the average randomizations per site by as much as 149%.
- During the last two years of the study, Acurian delivered 75% of the US randomizations and 29% of randomizations overall.



By increasing site enrollment rates, Acurian helped the sponsor reach its randomization commitments by as much as 256 days faster vs. waiting for sites to find enough patients, unassisted.



**WHEN YOU CAN'T AFFORD A DELAY  
IN PATIENT ENROLLMENT**

Acurian, Inc. is the leading full-service provider of global patient enrollment and retention solutions for the life sciences industry. For the past 20 years, our unique patient-first approach has provided sponsors with enrollment certainty by delivering the patients they need, when and where they need them.

www.acurian.com  
enrollment.certainty@acurian.com  
146020166

**United States**  
Horsham, Pennsylvania  
215.323.9000

**Europe**  
Cambridge, United Kingdom  
+44 1223 374799